March 2023, Vol 13, No 3

An analysis from the ARASENS trial showed that the addition of darolutamide (Nubeqa) to androgen-deprivation therapy (ADT) and docetaxel significantly improved overall survival (OS) in subgroups of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with high-volume and high-risk disease and should be considered the new standard of care for this patient population. Read More ›

Older Black and Hispanic patients with advanced cancer are less likely than White patients to receive opioid medications for pain relief in the last weeks of life, according to the results of a recent study. Read More ›

Researchers at Penn State have successfully 3D bioprinted breast cancer tumors and treated them in a breakthrough study to better understand the disease that is one of the leading causes of mortality worldwide. Read More ›

The decision to use adjuvant therapies in patients with renal-cell carcinoma (RCC) should be based on risk, patient goals, and shared decision-making. This topic was explored in a presentation by Matthew Zibelman, MD. Read More ›

Anticipated launches and uptake of biosimilars are predicted to increase spending to $129 billion and savings by $180 billion over the next 5 years, according to a report by IQVIA. Read More ›

Results from a recent study by Krupal B. Patel, MD, MSc, FRCSC, Surgeon, Department of Head and Neck–Endocrine Oncology, Moffitt Cancer Center, Tampa, FL, and colleagues indicate that the adoption of telehealth services during the pandemic saved patients with cancer both time and travel costs, reducing the cost burden associated with their care. Read More ›

Young women with early-stage, hormone receptor (HR)-positive breast cancer attempting to become pregnant can safely pause endocrine therapy and resume it later, according to initial results from the international POSITIVE trial. Read More ›

In a new study published in the Journal of Managed Care & Specialty Pharmacy, Teresa Gibson, PhD, Professor of Practice, School of Mathematical Sciences, RIT, showed that an individual’s previous adherence behavior is an important predictor of future adherence. Read More ›

President Biden announced that the public health emergency (PHE) will expire on May 11, 2023. Providers need to review the impact of these upcoming changes, in addition to any others that bear weight on the financial stability of their practices or the ability of patients to access the care they need. Read More ›

On January 27, 2023, the FDA approved elacestrant (Orserdu; Stemline Therapeutics), an estrogen receptor (ER) antagonist, for the treatment of postmenopausal women or adult men with ER-positive, HER2-negative advanced or metastatic breast cancer and an ESR1 mutation whose disease progressed after ≥1 line of endocrine therapy. Read More ›